MASLD পৰীক্ষা: লেব, ফাইব্রোচিছ স্ক’ৰ আৰু ইমেজিং

MASLD পৰীক্ষাই আপোনাক কি ক’ব পাৰে আৰু কি ক’ব নোৱাৰে

মেটাবলিক ডিসফাংচন এসোসিয়েটেড ষ্টেট’টিক লিভাৰ ডিজিজে (MASLD) এতিয়াৰ ক্লিনিকাল ভাষাত পুৰণা পৰিভাষা NAFLD-ক প্ৰতিস্থাপন কৰিছে। ই যকৃতৰ ষ্টেট’চিছৰ সৈতে এটা বা তাতকৈ অধিক কাৰ্ডিঅ’মেটাবলিক ৰিস্ক ফেক্টৰ – যেনে ডাঙৰ কঁকালৰ পৰিধি, ডায়াবেটিচৰ পূৰ্ব অৱস্থা, ২ ধৰণৰ ডায়াবেটিস, উচ্চ ৰক্তচাপ, কম HDL কলেষ্টেৰল, বা উচ্চ ট্ৰাইগ্লিসাৰাইড – বৰ্ণনা কৰে আৰু যকৃতত চৰ্বিৰ প্ৰতিযোগিতামূলক কাৰণসমূহৰ এক চিন্তা-প্ৰসূত অনুসন্ধানৰ প্ৰয়োজন হয়।.

এইটো এক অস্বস্তিকৰ সত্য যে কোনো একক MASLD ৰক্ত পৰীক্ষাই এই ৰোগ নিৰ্ণয় কৰিব নোৱাৰে। ডঃ থমাছ ক্লেইন হিচাপে, মই ব্যাখ্যা কৰো যে ALT হৈছে এক পলায়ন সংকেত, চৰ্বি মাপক নহয়: ই যকৃত কোষৰ চাপৰ সৈতে বৃদ্ধি পাব পাৰে, তথাপি এজন ব্যক্তিৰ যথেষ্ট পৰিমাণে যকৃতৰ চৰ্বি বা সাধাৰণ ALT থকা ফাইব্ৰ’চিছ থাকিব পাৰে। আমাৰ যকৃত পেনেল গাইড এখন সাধাৰণ পেনেলত কি কি অন্তৰ্ভুক্ত আছে আৰু কি নাই তাৰ ব্যাখ্যা কৰে।.

কান্টেষ্টি হৈছে এক... এ আই ব্লাড টেষ্ট এনালাইজাৰ যিটোৱে AST, ALT, প্লেটলেট, গ্লুকোজ, HbA1c, ট্ৰাইগ্লিসাৰাইড, আৰু মদ্যপান-সম্পৰ্কীয় প্ৰসঙ্গসমূহক এক সময়সীমাত স্থাপন কৰে, এটা চিহ্নিত এনজাইমক ৰোগ নিৰ্ণয় হিচাপে গণ্য নকৰি। সেইটো গুৰুত্বপূৰ্ণ কাৰণ ৬-১২ মাহত এটা ধাৰাবাহিক বিপাকীয় ধৰণৰ পৰা, এটা কঠিন ৱৰ্কআউট, এটা নতুন ঔষধ, বা এটা ভাইৰেল অসুস্থতাৰ পিছত বৃদ্ধি পোৱা ALT খুব ভিন্নভাৱে ব্যাখ্যা কৰা হয়।.

ক্লিনিকাল উদ্দেশ্য হৈছে ফাইব্ৰ’চিছ ট্ৰায়াজ

MASLD থকা বেছিভাগ লোকৰ চিৰোছিছ নহয়। মূল পূর্বাভাসমূলক চলকটো হৈছে ফাইব্ৰ’চিছৰ পৰ্যায়, বিশেষকৈ F3–F4 পৰ্যায়, যাৰ বাবে আধুনিক পথবোৰ বিশেষ ইমেজিংৰ আগতে বিনামুলীয়া ৰক্ত-ভিত্তিক ট্ৰায়াজেৰে আৰম্ভ হয়।.

কাৰ চৰ্বিযুক্ত লিভাৰ পৰীক্ষা কৰা উচিত

২ ধৰণৰ ডায়াবেটিস হৈছে MASLD পৰীক্ষাৰ আটাইত কৈ স্পষ্ট ব্যৱহাৰিক ট্রিগাৰ কাৰণ ডায়াবেটিচে ষ্টেট’হেপাটাইটিচ আৰু ফাইব্ৰ’চিছৰ সম্ভাৱনা বৃদ্ধি কৰে, এমনকি এটা এনে শৰীৰৰ ওজনত যিটো উল্লেখযোগ্য নহয়। ২০২৪ চনৰ EASL-EASD-EASO নিৰ্দেশিকা অনুসৰি ২ ধৰণৰ ডায়াবেটিস, পেটৰ মেদবহুলতাৰ সৈতে বিপাকীয় ৰিস্ক, বা একেৰাহে বৃদ্ধি হোৱা যকৃতৰ এনজাইম থকা লোকসকলৰ MASLD-ৰ সৈতে ফাইব্ৰ’চিছৰ কেছ-ফাইন্ডিংৰ পৰামৰ্শ দিয়ে (EASL-EASD-EASO, 2024)।.

মই এনেকুৱা ঠুনুকা ৰোগীৰো পৰীক্ষা কৰোঁ যাৰ উচ্চ ট্ৰাইগ্লিসাৰাইড, উচ্চ ৰক্তচাপ, নিদ্ৰা apnea, পলিসিস্টিক অভেৰী সিনড্ৰোম, বা চিৰোছিছৰ কাষৰীয়া পৰিয়ালৰ ইতিহাস আছে। ইয়াত BMI তকৈ কঁকালৰ পৰিমাণ বেছিকৈ তথ্য দিব পাৰে; কেন্দ্ৰীয় adiposity বিপাকীয়ভাৱে সক্ৰিয়, আৰু মেটাবলিক সিনড্রোম কাটঅফ উপবাসে থকা গ্লুকোজ, ৰক্তচাপ, HDL, আৰু ট্ৰাইগ্লিসাৰাইডসমূহ একত্ৰিত কৰাত সহায় কৰে।.

সকলোৰে বাবে সাধাৰণ জনসংখ্যা আল্ট্রাসাউন্ডৰ বাবে একেধৰণৰ প্ৰমাণ নাই যিটো লক্ষ্যযুক্ত ৰিস্ক মূল্যায়নৰ বাবে আছে। যদি আপোনাৰ কোনো বিপাকীয় ৰিস্ক ফেক্টৰ নাই, সাধাৰণ যকৃতৰ পৰীক্ষাৰ ফলাফল আছে, আৰু কোনো সম্পৰ্কীয় পৰিয়াল বা ঔষধৰ ইতিহাস নাই, তেন্তে নিৰ্বিচাৰ চৰ্বিযুক্ত যকৃতৰ পৰীক্ষাৰ ফলত দুৰ্ঘটনাবশতঃ তথ্য পোৱা যাব পাৰে কিন্তু ফলাফলৰ উন্নতি নহ’ব।.

Pregnancy and children need separate pathways

Pregnancy alters liver tests and is not a suitable time to apply adult fibrosis scores without clinician input. In children, paediatric reference ranges and specialist pathways are needed; adult FIB-4 cutoffs should not be used.

MASLD_ৰ সাধাৰণ ৰক্ত পৰীক্ষা: ব্যৱহাৰযোগ্য প্ৰথম পেনেল

ALT and AST are measured in U/L, but their laboratory upper limits vary substantially by country and assay. AASLD notes that ALT values of 29–33 U/L আৰু কিন্তু কিছুমান ইউৰোপীয় আৰু hepatology-কেন্দ্ৰিক ৰেঞ্জে নিম্ন সীমা ব্যৱহাৰ কৰে। American College of Gastroenterology-ৰ গাইডলাইনত উল্লেখ আছে যে সুস্থ স্বাভাৱিক ALT পুৰুষৰ ক্ষেত্ৰত প্ৰায় are more clinically appropriate than many laboratory reference limits for chronic liver injury; an ALT of 38 U/L may therefore deserve attention despite appearing only mildly raised (Rinella et al., 2023).

GGT is not a MASLD diagnostic test, yet it is often helpful when ALT is mildly elevated and alcohol, medication, or biliary disease is part of the differential. A disproportionate alkaline phosphatase or GGT rise, especially with direct bilirubin elevation, shifts the investigation toward cholestasis rather than uncomplicated steatosis; see our guide to ALP, GGT and bilirubin patterns.

Albumin, bilirubin, and INR are measures of liver synthetic function, not early fat accumulation. Albumin below about 35 g/L, rising bilirubin, or an elevated INR in someone with suspected chronic liver disease deserves prompt medical review because these abnormalities may indicate advanced disease or another process entirely.

লিভাৰত চৰ্বি কিয় জমা হয়, তাৰ কাৰণ ব্যাখ্যা কৰা মেটাবলিক পৰীক্ষা

HbA1c of 5.7–6.4% প্রি-ডায়াবেটিচ সূচিত কৰে, আনহাতে 6.5% বা তাতকৈ ওপৰক on an appropriate confirmatory pathway supports diabetes. In clinic, I am particularly alert to a patient with HbA1c 6.1%, triglycerides 220 mg/dL, and an ALT near the laboratory limit: that combination can signal insulin resistance long before overt diabetes appears.

ট্রাইগ্লিসারাইডের 150 mg/dL বা অধিক are one metabolic syndrome criterion, and levels above 500 mg/dL shift the immediate concern toward pancreatitis prevention. A non-fasting sample is often adequate for cardiovascular assessment, but fasting triglycerides can clarify a confusing result; our article on খোৱাৰ পিছত ট্ৰাইগ্লিচাৰাইড সম্পৰ্কীয় গাইড চাওক ব্যৱহাৰিক ভিন্নতা সামৰি লয়।.

Fasting insulin and HOMA-IR can be informative in selected patients, but neither is required to diagnose MASLD or calculate fibrosis risk. I caution against chasing insulin numbers alone: insulin assays differ between laboratories, whereas HbA1c, glucose, waist size, and triglyceride trends usually guide decisions more reliably.

Normal HbA1c does not erase metabolic risk

A person can have normal HbA1c and still have MASLD, particularly with visceral adiposity, genetic susceptibility, or high triglycerides. HbA1c also becomes less reliable after transfusion, with some haemoglobin variants, and in conditions that change red-cell lifespan.

লিভাৰৰ অন্যান্য কাৰণসমূহ নাকচ কৰিবলৈ চিকিৎসকসকলে ব্যৱহাৰ কৰা পৰীক্ষা

Hepatitis B surface antigen and hepatitis C antibody are common early checks when aminotransferases remain elevated. A person may have both MASLD and viral hepatitis, so finding metabolic risk factors should never stop a standard liver work-up; our overview of hepatitis C testing clues explains why symptoms are often absent.

Ferritin is frequently raised in MASLD because it behaves as an acute-phase reactant, not necessarily because iron stores are excessive. Ferritin above মহিলাসকলৰ ক্ষেত্ৰত 300 ng/mL অথবা পুৰুষসকলৰ ক্ষেত্ৰত 400 ng/mL can prompt iron studies, but transferrin saturation persistently above 45% is the more useful clue that hereditary haemochromatosis may need evaluation; see iron overload lab clues.

Autoimmune markers, immunoglobulins, ceruloplasmin, alpha-1 antitrypsin testing, and medication review are selective—not blanket—tests. In a 28-year-old with ALT 180 U/L and no metabolic risk, I would not be reassured by a slightly fatty ultrasound; age and the enzyme pattern make alternative causes much more important.

Alcohol quantity changes the diagnostic label

As of September 15, 2026, EASL describes MetALD when MASLD coexists with alcohol intake of 20–50 g/day in women or 30–60 g/day in men. Amount, frequency, binge pattern, prior use, and under-reporting all affect interpretation, so a single yes-or-no alcohol question is inadequate.

FIB-4: জনাটো প্ৰথম ফাইব্ৰোচিছ স্ক’ৰ

The formula is age × AST divided by platelet count × the square root of ALT; calculator outputs are safer than manual arithmetic because platelets may be reported as 10⁹/L or 10³/µL. FIB-4 is designed to rule out advanced fibrosis efficiently, not to prove cirrhosis, and our FIB-4 calculation guide walks through the units.

For people over 65 years, using the usual 1.3 threshold creates many false alarms because age is part of the formula. A cutoff of 2.0 is preferred for low-risk exclusion in this group; conversely, FIB-4 performs poorly below age 35 and should not be treated as a clean bill of liver health in younger adults.

Do not calculate FIB-4 during pneumonia, a severe flare of illness, acute hepatitis, or immediately after an event likely to raise AST or lower platelets. A 52-year-old marathon runner with AST 89 U/L after a race can generate a misleading score—muscle stress and temporary enzyme shifts are not liver fibrosis.

FIB-4_ৰ পিছত দ্বিতীয় স্তৰৰ MASLD ৰক্ত পৰীক্ষা

The Enhanced Liver Fibrosis test combines hyaluronic acid, PIIINP, and TIMP-1—markers related to matrix turnover rather than liver enzymes. In AASLD pathways, an ELF score of 9.8 or higher can identify people at increased risk of advanced fibrosis, and 11.3 or higher is associated with a higher risk of liver-related events in advanced disease.

কান্টেষ্টি হৈছে এক... AI lab test interpretation service-ত that can identify when the exact ingredients needed for FIB-4 are present and flag when a result sits in the indeterminate zone. It cannot order imaging, establish fibrosis stage, or substitute for a clinician examining the complete record; those boundaries are deliberate.

Scores such as APRI, NAFLD Fibrosis Score, and FAST may appear in specialist letters, but they are not interchangeable. APRI can be distorted by non-liver AST elevations, while the NAFLD Fibrosis Score includes BMI and albumin; a falling platelet trend is often more actionable than any one borderline algorithm result, as discussed in our cirrhosis lab clues.

Why fibrosis biomarkers occasionally disagree

Inflammatory illness, reduced kidney function, congestive heart failure, and age can influence some fibrosis markers. When a low FIB-4 and high ELF conflict, elastography and specialist review are usually more useful than repeating both tests immediately.

আল্ট্ৰাছাউণ্ড আৰু ইলাষ্ট’গ্ৰাফি: ইমেজিং কি যোগ কৰে

Standard ultrasound is accessible and useful, but it misses mild fat accumulation and cannot reliably stage fibrosis. A report stating “echogenic liver” supports steatosis in the right clinical context; it does not tell you whether liver cells are inflamed or whether fibrosis is progressing.

Transient elastography sends a painless vibration through the liver to estimate stiffness in kilopascals. In common MASLD pathways, less than 8 kPa suggests low risk of advanced fibrosis, 8–12 kPa is a grey zone, and above 12 kPa increases concern—yet meals, acute inflammation, congestion, cholestasis, and measurement quality can all raise stiffness.

I ask patients to fast for at least ৩ ঘণ্টা before elastography when their centre requests it, because a recent meal can transiently increase stiffness. Higher BMI may require an XL probe, and a technically limited scan should be repeated rather than treated as bad news; our high AST follow-up guide helps explain why AST needs context.

CAP is a fat estimate, not a fibrosis stage

Controlled attenuation parameter, or CAP, estimates ultrasound signal loss caused by liver fat. Its values are device-specific and less useful for monitoring small changes than for supporting the overall diagnosis of steatosis.

MRI-PDFF আৰু MRE: বিশেষ পৰীক্ষাৰ ইমেজিং কেতিয়া সহায় কৰে

MRI-PDFF measures the proportion of mobile protons attributable to fat and is excellent for research, trials, and ambiguous cases. A fall of roughly 30% relative MRI-PDFF has been associated with histologic improvement in treatment studies, but this is not a personal treatment target to pursue without specialist guidance.

MRE samples a much larger portion of liver than a small tissue core and can be especially helpful when transient elastography is unreliable. In specialist algorithms, MRE stiffness around 3.6 kPa or higher raises concern for advanced fibrosis, though scanner method and clinical setting affect the threshold.

Neither MRI test is routinely necessary for a low FIB-4, normal synthetic function, and reassuring elastography. The expensive scan is most valuable when it resolves a genuine decision: for example, conflicting blood scores in a person being considered for hepatology follow-up, not simply because an ultrasound found fat.

Imaging does not replace cardiometabolic care

A precise liver-fat percentage does not measure cardiovascular risk, which remains a leading cause of illness in MASLD. Lipids, blood pressure, diabetes treatment, sleep apnoea, and smoking status still need active management.

লিভাৰ বায়োপ্সি কেতিয়াও বিবেচনা কৰা হয়

A tissue examination can distinguish simple steatosis from steatohepatitis and stage fibrosis directly, but a tiny core may not represent the whole liver. Sampling variation is one reason I do not present biopsy as an automatic “gold standard” answer when high-quality elastography and blood tests agree.

Biopsy discussions are more common with unexplained ALT elevations above ৬ মাহ, suspected autoimmune hepatitis, high ferritin with possible iron overload, or discordant tests such as FIB-4 0.8 with stiffness 15 kPa. The decision should include bleeding risk, medication review, and whether the result will change treatment or surveillance.

Dr. Thomas Klein’s practical rule is simple: test escalation should answer a question that changes the plan. Kantesti AI organizes longitudinal results for that conversation, while our চিকিৎসাগত বৈধতা (medical validation) পদ্ধতি describes why algorithmic interpretation is designed as decision support, not diagnosis.

A biopsy result can still be incomplete

Fibrosis can be unevenly distributed, and steatohepatitis activity can fluctuate with recent weight change, alcohol use, and medications. A low-stage biopsy from years ago should not override new signs of portal hypertension or worsening non-invasive tests.

MASLD_ৰ সাধাৰণ ফলাফলৰ ধৰণ আৰু ইয়াৰ অৰ্থ

Pattern one is ALT 45 U/L, AST 32 U/L, platelets 260 ×10⁹/L, HbA1c 6.2%, and triglycerides 210 mg/dL. This is a reasonable setting for FIB-4 and metabolic intervention, but it is not proof of advanced disease; repeating the panel after addressing alcohol and medication confounders is often sensible.

Pattern two is AST 58 U/L, ALT 45 U/L, platelets 135 ×10⁹/L, and FIB-4 above 2.67. The combination of AST predominance and declining platelets deserves urgent fibrosis assessment because platelets may fall as portal pressure rises—although alcohol, immune conditions, and laboratory artefact also need consideration.

Kantesti AI interprets MASLD-related biomarkers by comparing present results with prior values, age-adjusted FIB-4 thresholds, and coexisting metabolic markers rather than assigning meaning to an isolated high flag. A sudden platelet change should also prompt a check for EDTA প্লেটলেট গোট খোৱা, which can create a falsely low count.

AST:ALT ratio is a clue, not a verdict

An AST:ALT ratio above 1 can occur with advanced fibrosis, alcohol exposure, muscle injury, or cirrhosis, but it is not diagnostic by itself. Creatine kinase can help when strenuous exercise or muscle symptoms make AST origin uncertain.

MASLD পৰীক্ষা কিমান বাৰ পুনৰাবৃত্তি কৰিব

Liver enzymes can move by 10–20% between visits because of exercise, alcohol, intercurrent illness, weight change, and ordinary biological variation. A repeat result is more useful when it is collected under comparable conditions: avoid unusually hard exercise for 48–72 hours, disclose supplements, and use the same laboratory where practical.

Weight loss can briefly raise ALT during rapid fat mobilisation, particularly in the first few weeks of a restrictive programme. That short-lived rise should be interpreted alongside symptoms, bilirubin, alkaline phosphatase, and the magnitude of change; our guide to ওজন কমোৱাৰ পিছত ALT এই বিপৰীতমুখী ধৰণটো ব্যাখ্যা কৰে।.

কান্টেষ্টি হৈছে এক... এআই বায়োমাৰ্কাৰ ইণ্টাৰপ্ৰিটেশন প্লেটফৰ্ম that lets people compare serial liver, glucose, lipid, and platelet results without losing the original laboratory ranges. Trend graphs are useful prompts for a clinician conversation, but a stable-looking graph does not replace fibrosis reassessment at the recommended interval.

Do not repeat a fibrosis score during acute illness

FIB-4 should be deferred until acute illness has resolved because AST and platelet count may be temporarily distorted. In my experience, repeating a score 4–12 weeks after recovery is often more informative than acting on an inpatient calculation.

MASLD ৰক্ত পৰীক্ষা আৰু স্কেনৰ বাবে কেনেদৰে প্ৰস্তুত হ’ব

Bring an accurate list of prescriptions, over-the-counter pain medicines, bodybuilding products, herbal preparations, and recent antibiotics. Supplements marketed for “detox” are not automatically benign; concentrated green tea extract, anabolic products, and multi-ingredient preparations can cause liver injury, as reviewed in our liver supplement safety article.

Avoid binge alcohol and unusually intense exercise for 48–72 ঘণ্টা before a planned liver panel if the aim is to establish a baseline, unless your clinician has told you otherwise. Do not stop prescribed medicines simply to improve a result; write down timing and dose so the interpreting clinician can account for them.

For ultrasound or elastography, ask whether your local service requests fasting and whether you need an XL probe because of body size. A failed or technically unreliable scan is a quality issue, not a personal failure, and repeating it at an experienced centre is entirely reasonable.

Save context with each result

Record recent illness, alcohol intake, exercise, new medications, and weight change beside the laboratory date. This simple habit can prevent a harmless transient ALT rise from becoming months of unnecessary anxiety.

তাৎক্ষণিক লিভাৰ পৰ্যালোচনাৰ প্ৰয়োজনীয় কিছুমান ‘red flag’

Urgent review is also appropriate for ALT or AST above 10 times the local upper limit, bilirubin above 3 mg/dL বা প্ৰায় ৫০ µmol/L with symptoms, INR elevation not explained by anticoagulants, or new platelets below 100 ×10⁹/L. These cutoffs are triage signals, not a diagnosis, and local emergency advice should take precedence.

Referral to hepatology is usually appropriate for FIB-4 above 2.67, elastography above about 12 kPa, suspected cirrhosis, unexplained persistent aminotransferase elevation, or diagnostic uncertainty. The question is not whether a patient has “failed” lifestyle change; it is whether they need surveillance for portal hypertension, liver cancer, or complications.

Kantesti-ৰ চিকিৎসা বিষয়বস্তু আমাৰ মেডিকেল এডভাইজাৰী ব’ৰ্ড, but an app cannot evaluate jaundice, abdominal tenderness, mental status, or fluid retention. If symptoms are new or escalating, seek in-person care first and interpret uploaded results afterward.

Symptoms are often absent until late disease

Early fibrosis commonly causes no specific symptom, which is why risk-based testing matters. Conversely, fatigue alone is common and should not be assumed to be from MASLD without evaluating sleep, thyroid disease, anaemia, mood, and medication effects.

MASLD_ৰ ফলাফলৰ পিছত ৰোগী-কেন্দ্ৰিক পৰিকল্পনা

Ask your clinician four concrete questions: Do I have confirmed steatosis? What is my FIB-4 with the correct age cutoff? Do I need elastography or ELF? When should we repeat testing? These questions turn a vague “fatty liver” label into a plan with measurable checkpoints.

For many patients, a sustained 5% weight reduction improves liver fat, while 7–10% is more likely to improve steatohepatitis and fibrosis-related measures; the precise response varies with diabetes treatment, physical activity, sleep, genetics, and alcohol. Mediterranean-style eating, resistance training, aerobic activity, and evidence-based treatment of diabetes or obesity belong in the same plan, not in competing camps.

Kantesti AI is used by people across 127 countries to organise multilingual laboratory reports and track changes between appointments. If you want to understand how result extraction and pattern analysis work, our AI প্রযুক্তি গাইড explains the safeguards; your treating clinician remains the person who confirms diagnosis and treatment.

What improvement looks like

Improvement may appear as lower triglycerides, better HbA1c, a falling ALT, stable platelets, and reassuring fibrosis assessment—not necessarily a perfect enzyme value at every draw. A result trend should be judged over months, not days.

সঘনাই সোধা প্ৰশ্ন